<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734550</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0087</org_study_id>
    <secondary_id>01EO1502</secondary_id>
    <secondary_id>U1111-1181-8724</secondary_id>
    <secondary_id>DRKS00010285</secondary_id>
    <nct_id>NCT02734550</nct_id>
  </id_info>
  <brief_title>(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis</brief_title>
  <acronym>CandiSep</acronym>
  <official_title>(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection Versus Culture Based Diagnosis in Patients With Severe Sepsis or Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Sepsis Control and Care, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Clinical Studies, University Hospital Jena, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dept. of Microbiology, University Hospital Erlangen, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Medical Statistics, Computer Sciences and Documentation, University Hospital Jena, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal Ministry of Education and Research, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Associates of Cape Cod, Inc., East Falmouth, MA, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Sepsis Control and Care, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized multicenter study evaluates whether the decision to prescribe
      antifungals guided by (1,3)-β-D-glucan in comparison to standard of care shortens time to
      antifungal therapy and reduces mortality in patients with severe sepsis or septic shock and a
      high risk of invasive candida infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (1,3)-β-D-glucan is a component of the cell wall of many fungi including candida spp. and is
      present in the blood of patients with invasive candida infection (ICI). Several studies
      showed a good diagnostic accuracy (1,3)-β-D-glucan in predicting ICI. However, others have
      challenged (1,3)-β-D-glucan as a diagnostic tool in critically ill patients as many
      substances used in the intensive care unit might affect the results of the assay. The goal of
      this study is to investigate whether (1,3)-β-D-glucan can early identify sepsis patients in
      need of antifungal therapy. Patients randomized to the standard of care group receive
      antifungals depending on microbiological results according to current guidelines. Patients
      randomized to the BDG group receive antifungals depending on the (1,3)-β-D-glucan plasma
      concentration on day 1 and day after diagnosing sepsis. Therapy may be modified according to
      microbiological results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2016</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">August 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>investigator-initiated prospective, multicenter, randomized, open, and parallel group study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>28 day antifungal-free survival</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Candida Colonization</measure>
    <time_frame>14 days</time_frame>
    <description>Candida colonization assessed by Candida Colonization Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to antifungal therapy</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of organ support</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean total SOFA score</measure>
    <time_frame>14 days</time_frame>
    <description>Measure of organ dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital length of stay</measure>
    <time_frame>Hospital length of stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital mortality</measure>
    <time_frame>Hospital length of stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of (1,3)-β-D-glucan in comparison to PCR and other experimental diagnostics</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">342</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diagnosis of invasive candida infection according to standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(1,3)-β-D-glucan guidance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment according to BDG-result</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.</description>
    <arm_group_label>(1,3)-β-D-glucan guidance</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>(1,3)-β-D-glucan guided therapy</intervention_name>
    <description>Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.</description>
    <arm_group_label>(1,3)-β-D-glucan guidance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe sepsis or septic shock

          -  Onset of sepsis no longer than 24 hours

          -  Increased risk of invasive candida infection with at least one of the following
             criteria:

               -  total parenteral nutrition ≥48 hours

               -  abdominal surgery within the last 7 days

               -  antimicrobial therapy for at least 48 hours within the last 7 days

               -  Acute or chronic renal failure with renal replacement therapy

          -  Age ≥18 years

          -  Informed consent of the patient or legal representative or delayed consent process is
             started if patient is incapable of giving informed consent and no legal representative
             is available.

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Ongoing invasive candida infection

          -  systemic antifungal therapy

          -  liver cirrhosis Child C

          -  cardiopulmonary bypass within the last 4 weeks

          -  treatment with immunoglobulins within the last 14 days

          -  immunosuppression (solid organ transplantation, AISA, leukopenia)

          -  participation in another intervention study

          -  no commitment to full therapy (i.e. DNR order)

          -  Infauste Prognose aufgrund von Nebenerkrankungen

          -  kin to or colleague of study personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Bloos, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jena University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Emden</name>
      <address>
        <city>Emden</city>
        <zip>26721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Göttingen</name>
      <address>
        <city>Gottingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Halle</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jena University Hospital</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie Klinikum</name>
      <address>
        <city>Siegen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Bloos F, Held J, Schlattmann P, Brillinger N, Kurzai O, Cornely OA, Thomas-Rüddel D. (1,3)-β-D-glucan-based diagnosis of invasive Candida infection versus culture-based diagnosis in patients with sepsis and with an increased risk of invasive Candida infection (CandiSep): study protocol for a randomized controlled trial. Trials. 2018 Sep 4;19(1):472. doi: 10.1186/s13063-018-2868-0.</citation>
    <PMID>30180873</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Invasive Candida Infection</keyword>
  <keyword>Biomarker</keyword>
  <keyword>(1,3)-β-D-glucan</keyword>
  <keyword>Antifungal therapy</keyword>
  <keyword>Intensive care medicine</keyword>
  <keyword>Critically ill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

